Plain-English translation of NCT06919965 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new treatment called erdafitinib — a medication delivered directly into the bladder — to see if it works better than standard chemotherapy drugs for people with high-risk bladder cancer. You would have already tried BCG treatment (a common bladder cancer therapy) before joining this study. The trial will compare how well this medication keeps cancer from coming back compared to chemotherapy options your doctor might normally choose.
Many people with high-risk bladder cancer don't respond well enough to standard BCG treatment, and their doctors need better options to prevent the cancer from returning or progressing. This trial tests whether this new medication delivered directly into the bladder might work better than the chemotherapy drugs currently available.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new treatment or standard chemotherapy (your doctor's choice of or ). If you receive , it will be inserted into your bladder on the first day and remain there for approximately 2 years. If you receive chemotherapy, you'll have weekly treatments for 4–6 weeks, followed by monthly treatments for up to a year (with possible additional treatment in year two). The trial will monitor how long you stay cancer-free and track any side effects throughout the study.
AI-generated summary from trial data · Oct 3, 2026 · Not medical advice
United States